Still the most popular type of cell-based assays for HTS are assays that use end-point readouts. In this category, we routinely develop:
All assays routinely run at a volume of 4–5 μl in the 384-well or 1,536-well plate format.
For deeper characterization of compounds at later stages of the hit-to-lead phase, we also use a wide variety of additional assays.
For difficult target classes, such as ion channels (e.g., potassium channels) or GPCRs, we also offer high-resolution kinetic assays. In addition, we offer analysis of calcium dynamics in iPSC-induced cardiomyocytes or neurons. Full-deck library screens (2.4 million compounds and beyond) or regular compound testing can be carried out.
We use the industry standard FLIPR® platform with one FLIPR® Tetra and one FLIPR® Penta. For high-throughput applications, we utilize 384- or 1,536 pipettor heads. Multi-addition assays can be developed according to your needs.
To better understand the dynamics of cell–drug response, we also offer multidimensional time-lapse imaging via high-content analysis. These assays include, among others, cell-cycle assays, autophagy assays, multi-target translocation assays, the determination of degradation kinetics, or Ca2+ flux in sub-cellular compartments.
HCA is an increasingly important field for the pharmaceutical industry to better understand spatial and temporal phenotypic changes in the cell. We consider HCA to be a vital part of the early drug discovery process and dedicate an entire platform to it. Here, you have access to the full potential of high-content imaging and analysis. In the past, a wide range of assays have been developed and successfully used to screen compound libraries of up to 4.5 million compounds. Read more about our HCA platform.